Ahead of today's review of Retacrit, Pfizer’s proposed biosimilar of Amgen’s epoetin alfa (Epogen) by the FDA’s Oncologic Drugs Advisory Committee (ODAC), committee members expressed positive views of the drug’s similarity to the reference drug Epogen.
In a review document posted on the FDA website, agency reviewers called Pfizer’s product “highly similar” to Amgen’s Epogen (and Johnson & Johnson’s Procrit, which is the same drug but is marketed for different uses under a licensing arrangement with a California biotech), and wrote that despite minor differences in clinically inactive components, the similarity stood. They further state that there are no clinically meaningful differences between the biosimilar and reference products in terms of the safety, purity, and potency. Pfizer hopes to gain approvals for Retacrit in each of Epogen’s 4 indications:
If approved, Retacrit will be Pfizer’s second biosimilar to be marketed in the United States. Inflectra, Pfizer’s biosimilar of infliximab (Remicade), was approved in November 2016. If approved, Retacrit would also be the second biosimilar approval to compete directly with an Amgen reference biologic product. Amgen is already facing competition from filgrastim-sndz (Zarxio), an approved biosimilar of filgrastim (Neupogen).
Retacrit’s approval, while likely, is not assured. Retacrit has faced prior regulatory denial: in 2015, the FDA issued a complete response letter to Pfizer following Pfizer’s acquisition of Hospira, which had developed the drug. And even if Retacrit is approved, a legal battle with Amgen looms over the marketing of Retacrit. Amgen is suing in federal court to block the launch of Retacrit, alleging that Hospira provided Amgen with notice of commercial launch too soon in the “patent dance” process laid out in the Biologics Price Competition and Innovation Act.
Epogen and Procrit are blockbuster drugs, with each earning over $1 billion in worldwide sales in 2016. Another Epogen biosimilar is likely to add to the competition with Amgen: Sandoz is also preparing to submit an application to the FDA for its Epogen biosimilar.
*Update: Pfizer announced in a press release that ODAC recommended approval of the company's epoetinalpha biosimilar across all the indications listed above. the recommendation will come into play when the FDA evaluates Pfizer's Biologics Licence Application for the proposed epoetin alfa biosimilar.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.